SAMSUNG BIOLOGICSSAMSUNG BIOLOGICSSAMSUNG BIOLOGICS

SAMSUNG BIOLOGICS

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪70.82 T‬KRW
15,000KRW
‪857.69 B‬KRW
‪3.69 T‬KRW
‪18.11 M‬
Beta (1Y)
0.44
Employees (FY)
‪4.42 K‬
Change (1Y)
−107 −2.36%
Revenue / Employee (1Y)
‪641.23 K‬KRW
Net income / Employee (1Y)
‪148.86 K‬KRW

About SAMSUNG BIOLOGICS


CEO
John Chongbo Rim
Headquarters
Inchon
Founded
2011
ISIN
KR7207940008
FIGI
BBG00DLBLKV1
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical products. It operates through the CDMO and Biopharmaceutical Development and Commercialization business divisions. The CDMO division provides development services from cell line development to early clinical trials, including cell line development, processes, formulations, and analysis methods. The Biopharmaceutical Development and Commercialization division focuses on the development and commercialization of biosimilars and is conducting research and development on various disease fields such as autoimmune diseases, cancer diseases, ophthalmic diseases, and blood diseases. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 207940 is 1,004,000 KRW — it has increased by 0.90% in the past 24 hours. Watch SAMSUNG BIOLOGICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange SAMSUNG BIOLOGICS stocks are traded under the ticker 207940.
207940 stock has risen by 0.90% compared to the previous week, the month change is a 1.01% rise, over the last year SAMSUNG BIOLOGICS has showed a 36.78% increase.
We've gathered analysts' opinions on SAMSUNG BIOLOGICS future price: according to them, 207940 price has a max estimate of 1,400,000.00 KRW and a min estimate of 999,000.00 KRW. Watch 207940 chart and read a more detailed SAMSUNG BIOLOGICS stock forecast: see what analysts think of SAMSUNG BIOLOGICS and suggest that you do with its stocks.
207940 reached its all-time high on Oct 22, 2024 with the price of 1,113,000 KRW, and its all-time low was 124,000 KRW and was reached on Nov 10, 2016. View more price dynamics on 207940 chart.
See other stocks reaching their highest and lowest prices.
207940 stock is 1.90% volatile and has beta coefficient of 0.44. Track SAMSUNG BIOLOGICS stock price on the chart and check out the list of the most volatile stocks — is SAMSUNG BIOLOGICS there?
Today SAMSUNG BIOLOGICS has the market capitalization of ‪71.46 T‬, it has decreased by −0.96% over the last week.
Yes, you can track SAMSUNG BIOLOGICS financials in yearly and quarterly reports right on TradingView.
SAMSUNG BIOLOGICS is going to release the next earnings report on Jan 28, 2025. Keep track of upcoming events with our Earnings Calendar.
207940 earnings for the last quarter are ‪3.72 K‬ KRW per share, whereas the estimation was ‪3.59 K‬ KRW resulting in a 3.55% surprise. The estimated earnings for the next quarter are ‪3.69 K‬ KRW per share. See more details about SAMSUNG BIOLOGICS earnings.
SAMSUNG BIOLOGICS revenue for the last quarter amounts to ‪1.19 T‬ KRW, despite the estimated figure of ‪1.10 T‬ KRW. In the next quarter, revenue is expected to reach ‪1.24 T‬ KRW.
207940 net income for the last quarter is ‪264.47 B‬ KRW, while the quarter before that showed ‪317.99 B‬ KRW of net income which accounts for −16.83% change. Track more SAMSUNG BIOLOGICS financial stats to get the full picture.
No, 207940 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has ‪4.42 K‬ employees. See our rating of the largest employees — is SAMSUNG BIOLOGICS on this list?
Like other stocks, 207940 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAMSUNG BIOLOGICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAMSUNG BIOLOGICS technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAMSUNG BIOLOGICS stock shows the buy signal. See more of SAMSUNG BIOLOGICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.